Moreover, although we generated and validated a serum GP73-based prognostic nomogram for determining the 6-month and 1-year survival of patients with HCC treated with anti-angiogenic agents, we demonstrated the favorable anti-angiogenic potential of GP73 in clinical practice. This evidence concerns the gene GOLM1 and hepatocellular carcinoma.